Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
HUTCHMED (China) Limited - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HCM
Nasdaq
2834
www.hutch-med.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for HUTCHMED (China) Limited
HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia
- Nov 19th, 2026 3:00 am
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
- Nov 18th, 2026 5:00 pm
HUTCHMED (AIM:HCM) Stock Looks Overvalued On Current Earnings
- Nov 17th, 2026 2:15 pm
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
- Nov 15th, 2026 9:00 pm
3 British Healthcare Stocks With Revenue Growth Up To 13%
- Nov 13th, 2026 8:12 pm
UPDATE – International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026
- Nov 9th, 2026 9:56 am
UK Stock Market Today: FTSE 100 Futures Slip On Housing Weakness And Data Watch
- Nov 9th, 2026 12:08 am
Should Phase III Lung Cancer Data Require Action From Hutchmed (AIM:HCM) Investors?
- Nov 8th, 2026 2:11 am
British Healthcare Stocks To Watch In November 2026
- Nov 6th, 2026 7:15 pm
HUTCHMED (China) (AIM:HCM) Extends Lung Cancer Filing Run As Undervalued View Holds
- Nov 5th, 2026 6:21 pm
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026
- Nov 5th, 2026 6:35 am
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
- Nov 4th, 2026 5:00 pm
HUTCHMED (AIM:HCM) Stock May Look Rich As FDA Orphan Drug News Lands
- Nov 2nd, 2026 5:21 pm
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
- Nov 1st, 2026 5:00 pm
3 British Healthcare Stocks To Own In October 2026
- Oct 30th, 2026 7:12 pm
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
- Oct 28th, 2026 6:00 pm
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
- Oct 26th, 2026 6:00 pm
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
- Oct 26th, 2026 2:30 am
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
- Oct 25th, 2026 6:00 pm
What HUTCHMED (China) (AIM:HCM)'s GSK Licensing Deal Means For Shareholders
- Oct 25th, 2026 1:12 am
Scroll